Literature DB >> 27578526

The role of CD44 in glioblastoma multiforme.

Kelly L Mooney1, Winward Choy1, Sabrin Sidhu1, Panayiotis Pelargos1, Timothy T Bui1, Brittany Voth1, Natalie Barnette1, Isaac Yang2.   

Abstract

A transmembrane molecule with several isoforms, CD44 is overexpressed in many tumors and promotes tumor formation through interactions with the tumor microenvironment. CD44 has been implicated in malignant processes including cell motility, tumor growth, and angiogenesis. The role of CD44 has been examined in many cancer types. This paper provides, to our knowledge, the first focused review of the role of CD44 in glioblastoma multiforme (GBM), the most common and fatal of primary brain cancers. We summarize research that describes how CD44 promotes GBM aggressiveness by increasing tumor cell invasion, proliferation and resistance to standard chemoradiation therapy. Effects of CD44 inhibition in GBM are also explored. Clinical trials investigating CD44 targeting in CD44-positive solid tumors are underway, and the evidence presented here suggests that CD44 inhibition in GBM may be a promising therapy.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  CD44 protein; CD44v6 antigen; Glioblastoma multiforme

Mesh:

Substances:

Year:  2016        PMID: 27578526     DOI: 10.1016/j.jocn.2016.05.012

Source DB:  PubMed          Journal:  J Clin Neurosci        ISSN: 0967-5868            Impact factor:   1.961


  44 in total

1.  Immune and genomic correlates of response to anti-PD-1 immunotherapy in glioblastoma.

Authors:  Junfei Zhao; Andrew X Chen; Robyn D Gartrell; Andrew M Silverman; Luis Aparicio; Tim Chu; Darius Bordbar; David Shan; Jorge Samanamud; Aayushi Mahajan; Ioan Filip; Rose Orenbuch; Morgan Goetz; Jonathan T Yamaguchi; Michael Cloney; Craig Horbinski; Rimas V Lukas; Jeffrey Raizer; Ali I Rae; Jinzhou Yuan; Peter Canoll; Jeffrey N Bruce; Yvonne M Saenger; Peter Sims; Fabio M Iwamoto; Adam M Sonabend; Raul Rabadan
Journal:  Nat Med       Date:  2019-02-11       Impact factor: 53.440

2.  Blockade of transforming growth factor-β signaling enhances oncolytic herpes simplex virus efficacy in patient-derived recurrent glioblastoma models.

Authors:  Shinichi Esaki; Fares Nigim; Esther Moon; Samantha Luk; Juri Kiyokawa; William Curry; Daniel P Cahill; Andrew S Chi; A John Iafrate; Robert L Martuza; Samuel D Rabkin; Hiroaki Wakimoto
Journal:  Int J Cancer       Date:  2017-08-26       Impact factor: 7.396

3.  Molecular responses to immune checkpoint blockade in glioblastoma.

Authors:  Hirotaka Ito; Hiroshi Nakashima; E Antonio Chiocca
Journal:  Nat Med       Date:  2019-03       Impact factor: 53.440

4.  Truncated Glioma-Associated Oncogene Homolog 1 (tGLI1) Mediates Mesenchymal Glioblastoma via Transcriptional Activation of CD44.

Authors:  Tadas K Rimkus; Richard L Carpenter; Sherona Sirkisoon; Dongqin Zhu; Boris C Pasche; Michael D Chan; Glenn J Lesser; Stephen B Tatter; Kounosuke Watabe; Waldemar Debinski; Hui-Wen Lo
Journal:  Cancer Res       Date:  2018-02-20       Impact factor: 12.701

5.  Surfen-mediated blockade of extratumoral chondroitin sulfate glycosaminoglycans inhibits glioblastoma invasion.

Authors:  Meghan T Logun; Kallie E Wynens; Gregory Simchick; Wujun Zhao; Leidong Mao; Qun Zhao; Subhas Mukherjee; Daniel J Brat; Lohitash Karumbaiah
Journal:  FASEB J       Date:  2019-08-09       Impact factor: 5.191

6.  Fabrication and Characterization of Chitosan-Hyaluronic Acid Scaffolds with Varying Stiffness for Glioblastoma Cell Culture.

Authors:  Ariane E Erickson; Sheeny K Lan Levengood; Jialu Sun; Fei-Chien Chang; Miqin Zhang
Journal:  Adv Healthc Mater       Date:  2018-06-11       Impact factor: 9.933

7.  Immunohistochemical Detection of Neural Stem Cells and Glioblastoma Stem Cells in the Subventricular Zone of Glioblastoma Patients.

Authors:  Vashendriya V V Hira; Remco J Molenaar; Barbara Breznik; Tamara Lah; Eleonora Aronica; Cornelis J F Van Noorden
Journal:  J Histochem Cytochem       Date:  2021-02-17       Impact factor: 2.479

8.  Interfering with hyaluronic acid metabolism suppresses glioma cell proliferation by regulating autophagy.

Authors:  Tao Yan; Xin Chen; Hua Zhan; Penglei Yao; Ning Wang; He Yang; Cheng Zhang; Kaikai Wang; Hong Hu; Jiafeng Li; Jingxian Sun; Yu Dong; Enzhou Lu; Zhixing Zheng; Ruotian Zhang; Xiaoxiong Wang; Jichao Ma; Ming Gao; Junyi Ye; Xinzhuang Wang; Lei Teng; Huailei Liu; Shiguang Zhao
Journal:  Cell Death Dis       Date:  2021-05-13       Impact factor: 8.469

9.  Identification of robust diagnostic and prognostic gene signatures in different grades of gliomas: a retrospective study.

Authors:  Jieting Liu; Hongrui Zhang; Jingyun Zhang; Zhitong Bing; Yingbin Wang; Qiao Li; Kehu Yang
Journal:  PeerJ       Date:  2021-05-11       Impact factor: 2.984

10.  Cystatin F acts as a mediator of immune suppression in glioblastoma.

Authors:  Emanuela Senjor; Milica Perišić Nanut; Barbara Breznik; Ana Mitrović; Jernej Mlakar; Ana Rotter; Andrej Porčnik; Tamara Lah Turnšek; Janko Kos
Journal:  Cell Oncol (Dordr)       Date:  2021-06-29       Impact factor: 6.730

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.